Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need. Lexeo Therapeutics concentrates on genetically defined cardiovascular conditions and APOE4-associated Alzheimer’s disease, using AAV-based programs designed to address the underlying causes of disease. Its current pipeline includes therapies such as LX2006 for Friedreich’s ataxia cardiomyopathy, LX2020 for PKP2-related arrhythmogenic cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer’s disease. The company operates as a biotechnology developer rather than a commercial drug maker, with its work centered on research, clinical development, and advancing precision medicines through early- and mid-stage testing. Based in New York City, Lexeo Therapeutics plays a specialized role in the genetic medicine market by targeting serious conditions where conventional treatments remain limited.
Website345 Park Avenue South
New York, NY, 10010
United States
The latest articles about LXEO.
Generated by AI
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
No summary yet.
Summary of Nov 17's posts. Generated by AI.
Investors talking about LXEO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.